Outcomes after virological failure to first-line second-generation INSTI-based therapy in a real-life setting

被引：0
|
作者：
Borjesson, R. Papaioannu [1 ]
Clemente, T. [1 ]
Diotallevi, S. [2 ]
Lolatto, R. [2 ]
Forniti, A. [3 ]
Bottanelli, M. [1 ]
Galli, L. [2 ]
Alberton, F. [1 ]
Muccini, C. [2 ]
Hasson, H. [2 ]
Castagna, A. [2 ]
Spagnuolo, V. [2 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] Ist Sci San Raffaele, Infect Dis Unit, Milan, Italy
[3] Univ Florence, Azienda Osped Univ Pisana, Infect Dis Unit, Florence, Italy
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
929
引用
收藏
页码：170 / 172
页数：3
相关论文
共 50 条
  • [21] Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda
    Reynolds, Steven J.
    Kityo, Cissy
    Mbamanya, Frank
    Dewar, Robin
    Ssali, Francis
    Quinn, Thomas C.
    Mugyenyi, Peter
    Dybul, Mark
    ANTIVIRAL THERAPY, 2009, 14 (02) : 293 - 297
  • [22] Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy
    Geretti, Anna M.
    Smith, Colette
    Haberl, Annette
    Garcia-Diaz, Ana
    Nebbia, Gaia
    Johnson, Margaret
    Phillips, Andrew
    Staszewski, Schlomo
    ANTIVIRAL THERAPY, 2008, 13 (07) : 927 - 936
  • [23] Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Konopleva, Marina
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 477 - 484
  • [24] Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.
    Smith, Denis
    Rouyer, Magali
    Mitry, Emmanuel
    Monnereau, Alain
    Cunha, Antonio Sa
    Bignon, Emmanuelle
    Le Monies, Alise
    Jove, Jeremy
    Noize, P.
    Moore, Nicholas
    Fourrier-Reglat, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
    Bar, Jair
    Peled, Nir
    Schokrpur, Shiruyeh
    Wolner, Mirjana
    Rotem, Ofer
    Girard, Nicolas
    Nana, Frank Aboubakar
    Derijcke, Sofie
    Kian, Waleed
    Patel, Sandip
    Gantz-Sorotsky, Hadas
    Zer, Alona
    Moskovitz, Mor
    Metro, Giulio
    Rottenberg, Yakir
    Calles, Antonio
    Hochmair, Maximilian
    Cuppens, Kristof
    Decoster, Lynn
    Reck, Martin
    Limon, Dror
    Rodriguez, Estelamari
    Astaras, Christoforos
    Bettini, Adrienne
    Hafliger, Simon
    Addeo, Alfredo
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 169 - 180
  • [26] UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
    Bar, J.
    Kian, W.
    Wolner, M.
    Derijcke, S.
    Girard, N.
    Rottenberg, Y.
    Dudnik, E.
    Metro, G.
    Hochmair, M. J.
    Aboubakar, F.
    Cuppens, K.
    Decoster, L.
    Reck, M.
    Limon, D.
    Calles Blanco, A.
    Astaras, C.
    Hafliger, S.
    Peled, N.
    Addeo, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S961 - S962
  • [27] Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting
    Monforte, Antonella d'Arminio
    Cozzi-Lepri, Alessandro
    Di Biagio, Antonio
    Marchetti, Giulia
    Lo Caputo, Sergio
    Rusconi, Stefano
    Gianotti, Nicola
    Mazzotta, Valentina
    Mazzarello, Giovanni
    Costantini, Andrea
    Castagna, Antonella
    Antinori, Andrea
    Monforte, A. d'Arminio
    Antinori, A.
    Andreoni, M.
    Castagna, A.
    Castelli, F.
    Cauda, R.
    Di Perri, G.
    Galli, M.
    Iardino, R.
    Ippolito, G.
    Lazzarin, A.
    Marchetti, G. C.
    Rezza, G.
    von Schloesser, F.
    Viale, P.
    Monforte, A. d'Arminio
    Antinori, A.
    Castagna, A.
    Ceccherini-Silberstein, F.
    Cozzi-Lepri, A.
    Girardi, E.
    Lo Caputo, S.
    Mussini, C.
    Puoti, M.
    Perno, C. F.
    Antinori, A.
    Balotta, C.
    Bandera, A.
    Bonora, S.
    Borderi, M.
    Calcagno, A.
    Capetti, A.
    Capobianchi, M. R.
    Castagna, A.
    Ceccherini-Silberstein, F.
    Cicalini, S.
    Cingolani, A.
    Cinque, P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1363 - 1367
  • [28] Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Garay, Carlos C.
    Hill, Jerrold W.
    Guo, Amy
    CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 256 - 261
  • [29] A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
    Calafiore, Valeria
    Giamporcaro, Silvia
    Conticello, Concetta
    Romano, Alessandra
    Parisi, Marina
    Giuffrida, Gaetano
    Tibullo, Daniele
    Di Raimondo, Francesco
    Santo Signorelli, Salvatore
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 14
  • [30] Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia
    Hudson, F. Parker
    Mulenga, Lloyd
    Westfall, Andrew O.
    Warrier, Ranjit
    Mweemba, Aggrey
    Saag, Michael S.
    Stringer, Jeffrey S. A.
    Eron, Joseph J.
    Chi, Benjamin H.
    ANTIVIRAL THERAPY, 2019, 24 (04) : 291 - 300
12345